Royal London Asset Management Ltd. Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Royal London Asset Management Ltd. grew its position in DexCom, Inc. (NASDAQ:DXCM) by 4.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 170,949 shares of the medical device company’s stock after buying an additional 7,711 shares during the quarter. Royal London Asset Management Ltd.’s holdings in DexCom were worth $13,295,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Harvest Fund Management Co. Ltd lifted its holdings in shares of DexCom by 42.5% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 26,307 shares of the medical device company’s stock worth $2,013,000 after buying an additional 7,848 shares during the period. Vinva Investment Management Ltd purchased a new stake in shares of DexCom in the 4th quarter worth $1,030,000. OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in shares of DexCom by 107.9% in the 4th quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,855 shares of the medical device company’s stock worth $533,000 after buying an additional 3,558 shares during the period. Intech Investment Management LLC lifted its holdings in shares of DexCom by 60.8% in the 4th quarter. Intech Investment Management LLC now owns 622,788 shares of the medical device company’s stock worth $48,434,000 after buying an additional 235,458 shares during the period. Finally, Generali Asset Management SPA SGR purchased a new stake in shares of DexCom in the 4th quarter worth $1,175,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Activity

In related news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 1.7 %

Shares of DXCM stock opened at $73.80 on Friday. The stock’s 50-day simple moving average is $83.33 and its 200-day simple moving average is $76.98. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $28.84 billion, a PE ratio of 51.61, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.